Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02104310 : A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Age ?18 years.

- Biopsy confirmed newly diagnosed or recurrent WHO Grade II or Grade III malignant
glioma, or Grade III malignant astrocytoma or oligoastrocytoma.

- Planned radiation treatments at Mayo Clinic Rochester.

- Willing to sign release of information for any follow-up records.

- Provide informed written consent.

- Willingness to participate in mandatory pre- and post-treatment imaging studies.

Exclusion Criteria:

- Patients diagnosed with WHO grade III oligodendroglioma or WHO grade IV malignant

- Patients previously treated with radiation therapy.

- Unable to undergo MRI scans with contrast (e.g. cardiac pacemaker, defibrillator,
kidney failure).

- Unable to undergo an 18F-DOPA PET scan (e.g. Parkinson's Disease, taking
anti-dopaminergic, or dopamine agonist medication or less than 6 half-lives from
discontinuance of dopamine agonists)

- Pregnant women

- Nursing women

- Men or women of childbearing potential who are unwilling to employ adequate
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557